Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Orchid genotyping deal smells sweet to Quest:

This article was originally published in Clinica

Executive Summary

Orchid BioSciences has licensed its proprietary SNP-IT technology for gene-based diagnostics testing services to Quest Diagnostics. Orchid received an initial fee and will earn royalties on all tests performed by Quest using the technology. The deal offered by Princeton, New Jersey-based Orchid is non-exclusive, and covers tests using SNAPShot reagent kits marketed by Applied Biosystems. Orchid Diagnostics, a newly formed strategic subunit led by COO Donald Marvin, says dealing with a company of the stature of Quest illustrates its success in providing biomedical applications to the entire spectrum of users - from early stage R&D to patients.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts